Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rimegepant - Biohaven Pharmaceuticals

Drug Profile

Rimegepant - Biohaven Pharmaceuticals

Alternative Names: BHV-3000; BMS-927711; NURTEC ODT; Rimegepant orally disintegrating tablet - Biohaven Pharmaceuticals; Rimegepant sulfate - Biohaven Pharmaceuticals; Rimegepant Zydis® ODT - Biohaven Pharmaceuticals; Rimegepant Zydis® oral fast-dissolve tablet - Biohaven Pharmaceuticals; Vydura

Latest Information Update: 18 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Biohaven Pharmaceuticals; Weill Cornell Medicine
  • Class 2 ring heterocyclic compounds; Amines; Analgesics; Antimigraines; Antipsoriatics; Carbamates; Cycloheptanes; Fluorobenzenes; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine
  • Phase II Plaque psoriasis; Trigeminal neuralgia

Most Recent Events

  • 09 Aug 2021 Biohaven Pharmaceuticals completes a phase II/III trial for Migraine (Prevention) in USA (PO) in February 2021 (NCT03732638)
  • 01 Jul 2021 Biohaven Pharmaceuticals has patent protection for rimegepant in the US
  • 01 Jul 2021 Biohaven Pharmaceuticals has patents pending for rimegepant in the Europe, Japan and China
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top